Literature DB >> 29150200

Extended-release naltrexone: good but not a panacea.

David C Lott1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29150200     DOI： 10.1016/S0140-6736(17)32872-6

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  3 in total

Review 1.  The relationship between incarceration history and overdose in North America: A scoping review of the evidence.

Authors:  Sasha Mital; Jessica Wolff; Jennifer J Carroll
Journal:  Drug Alcohol Depend       Date:  2020-05-24       Impact factor: 4.492

2.  Cost-Effectiveness of Buprenorphine-Naloxone Versus Extended-Release Naltrexone to Prevent Opioid Relapse.

Authors:  Sean M Murphy; Kathryn E McCollister; Jared A Leff; Xuan Yang; Philip J Jeng; Joshua D Lee; Edward V Nunes; Patricia Novo; John Rotrosen; Bruce R Schackman
Journal:  Ann Intern Med       Date:  2018-12-18       Impact factor: 25.391

3.  Comment on "Review of Case Narratives from Fatal Overdoses Associated with Injectable Naltrexone for Opioid Dependence".

Authors:  Bernard Silverman; Gary Bloomgren; Priya Jain; Kimberley Marcopul; Alexandra Silveira; James Fratantonio; Maria Sullivan; Sarah Akerman
Journal:  Drug Saf       Date:  2018-10       Impact factor: 5.606
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.